Pillar Biosciences Enhances Partnership with Illumina for NGS
Pillar Biosciences Expands NGS Partnership with Illumina
Pillar Biosciences, known for its innovation in Decision Medicine™, has recently expanded its collaboration with Illumina. This strategic partnership aims to integrate Pillar's next-generation sequencing (NGS) technology more robustly into Illumina's product offerings. This development marks a significant step forward in enhancing precision therapies for cancer patients.
New Tools for Oncology Panels
Under this partnership, a wider range of Pillar's oncoReveal™ NGS panels will now be directly available through Illumina. The recent launch of the MiSeq™ i100 Series has set an exciting stage for these advancements. Customers can soon access several of Pillar's oncology panels as part of validated libraries that are optimized for cutting-edge sequencing platforms. This move not only broadens the oncology panel portfolio but also aids researchers and clinicians in liquid biopsy applications.
Detailed Overview of Available Panels
The expanded oncology panels from Pillar Biosciences will include:
Liquid Biopsy Tumor Profiling
- oncoReveal™ Core LBx
- oncoReveal™ Essential LBx
- oncoReveal™ Fusion LBx
Solid Tumor Profiling
- oncoReveal™ Multicancer RNA Fusion (18-Driver gene RNA panel)
- oncoReveal™ Solid Tumor v2 (48-gene DNA panel)
Additional panels that leverage the newly launched Illumina MiSeq i100 Series encompass:
- oncoReveal Essential MPN
- oncoReveal Myeloid
- oncoReveal Multi-Cancer with CNV and Fusion Panel
- oncoReveal BRCA1 & BRCA2 plus CNV Panel
Industry Leaders Speak Out
Angela Ryan, Vice President of Product Management at Illumina, expressed enthusiasm for this partnership, emphasizing Illumina's dedication to offering a complete workflow solution for customers. She stated, "We are pleased to bring more oncology assays from Pillar Biosciences into our product lineup." This collaborative endeavor showcases a commitment to accelerating innovation in genomic profiling and cancer therapy.
Dan Harma, Chief Commercial Officer at Pillar Biosciences, also shared insights into the significance of this partnership, citing the rapid advancements in NGS technologies over the past 18 months. He noted, "By expanding the oncology offering with rapid, high-quality targeted genomic content, we can ensure more customers have a complete suite of NGS solutions to meet their needs." The partnership aims to maximize efficiency in testing processes, demonstrating a shared commitment to enhancing patient care.
About Pillar Biosciences
Pillar Biosciences stands at the forefront of Decision Medicine™, utilizing advanced NGS testing technology to refine the selection of targeted therapies for cancer patients. From tumor profiling through therapy selection to monitoring recurrences, Pillar aims to improve the overall diagnosing process. With proprietary technologies like SLIMamp® and PiVAT®, their testing solutions reduce costs while improving access and efficiency across the globe. Currently, the company boasts over 20 NGS testing kits in various development stages aimed at both IVD and RUO formats.
In conclusion, the expanded partnership between Pillar Biosciences and Illumina is set to deliver significant advancements in oncology. By merging their innovative technologies, they promise to enhance the landscape of NGS solutions, ultimately improving patient outcomes in cancer treatment.
Frequently Asked Questions
What is the focus of the partnership between Pillar Biosciences and Illumina?
The partnership aims to broaden the availability of Pillar's oncology NGS panels, integrating them into Illumina's sequencing platforms for improved cancer therapy.
What types of NGS panels are now available?
The collaboration supports both liquid and solid tumor profiling, featuring various oncoReveal™ panels tailored for specific genetic insights.
How do Pillar's technologies enhance NGS testing?
Pillar's proprietary SLIMamp® and PiVAT® technologies focus on localizing testing processes and reducing diagnostic costs, improving efficiency in cancer diagnostics.
What is Decision Medicine™?
Decision Medicine™ is an approach utilized by Pillar Biosciences that leverages accurate NGS testing to optimize therapy choices, providing personalized care for cancer patients.
How does this partnership impact cancer research?
By increasing the availability of effective NGS solutions, the partnership fosters advancements in cancer research and facilitates greater accessibility to genomic profiling.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- U.S. Stock Market Shows Strong Performance Amid Rising Sectors
- Oncocyte CEO to Present at LD Micro Conference in California
- Kinder Morgan's Quarterly Performance: Factors Impacting Earnings
- Banner Corporation Reports Strong Q3 Earnings Despite Revenue Setback
- Crown Castle Reports Strong Q3 Earnings Despite Revenue Drop
- Understanding Analyst Insights on Riot Platforms' Options Activity
- Compass Diversified Reveals Q3 2024 Earnings Call Details
- IAC Announces Earnings Release and Conference Call Details
- Wolfspeed Enhances Financial Agreement with Renesas for Growth
- Rexford Industrial's Impressive Q3 Performance and Future Outlook
Recent Articles
- sweetFrog® Unveils New Caramel Brownie Flavor for Winter
- Evolution Mining's Stock Downgrade: Insights and Implications
- Bicycle Therapeutics Reaches New Heights in Stock Performance
- Lightbridge Corporation Achieves 52-Week High Amid Challenges
- Goldman Sachs Upholds Buy Rating for ProLogis Amid 3Q Performance
- Epilepsy Foundation's Strategic Growth with New CFO Wanda Cook
- Terran Orbital Lawsuit Alert: Important Deadline for Investors
- BofA Securities Signals Strong Growth Prospects for Futu Holdings
- Join the Class Action for iLearningEngines, Inc. Investors
- Coinbase Stock Outlook: Volatility and Opportunities Ahead
- Neon EVM Innovates with Network Extensions for Solana Growth
- Class Action Updates: OM, SAGE, and SMCI Shareholder Rights
- Exploring CVS Health: The Pros and Cons of Division Separation
- Nano Nuclear Energy Soars Amid AWS Investment in Nuclear Power
- Understanding the Surge in Options Trading for Applied Digital
- Exploring AST SpaceMobile's Bullish Trends in Trading Options
- Understanding Uranium Energy's Recent Options Activity
- U.S. Bancorp Surprises with Strong Earnings Amid Market Gains
- Anticipating M&T Bank's Earnings: What Investors Should Know
- WD-40 Financial Forecast: What Investors Should Expect
- Insights into Commerce Bancshares' Upcoming Earnings Report
- Insights into Texas Capital Bancshares's Upcoming Earnings Report
- Exploring Snap-on's Upcoming Earnings Expectations
- Marten Transport Set to Reveal Quarterly Earnings Insights
- Yamazaki Home Launches Stunning Forest Green Collection
- Metropolitan Bank Holding: Insights Ahead of Earnings Release
- Investigation Launched into SBC Medical Group Holdings Inc.
- Insightful Earnings Projections for OceanFirst Financial OCFC
- William Blair Expands Cybersecurity Banking Team with New Leaders
- Unlocking Home Bancorp's Earnings Insights for Investors
- AI Council Initiative Boosts Insurance Collaboration with Tech
- Anticipating Earnings: Insights into Alpine Income Prop Trust
- Investors Can Lead Securities Fraud Action Against ALLR
- Eximia Research Enhances Clinical Trial Access with Strategic Expansion
- Baird Remains Optimistic on Twist Bioscience's Growth Prospects
- Kintara to After Reverse Split Transitions to TuHURA Biosciences
- Transformative Partnership: BAE Systems and Kongsberg Unite for Innovation
- Goldman Sachs Downgrades China Tourism Group Duty Free Stock
- Novavax Faces Challenges but Remains Optimistic for Value Growth
- First Community Corporation Stock Surges to New Milestone
- BlackBerry Outlines Bold Financial Targets for 2026 and 2027
- EDPR NA Distributed Generation Completes New Community Solar Projects
- UFPI Reaches New Heights: Stock Price Surges to $139.53
- NVR Achieves New Heights with Stock Price at $9927.82
- VAXA's Grant Highlights Impactful Food Nutrition Initiatives
- Eastern Bankshares Surges to 52-Week High Amid Growth Strategies
- Perella Weinberg Partners Achieves Historic Stock Milestone
- Belgium Market Adjustments: BEL 20 Experiences Slight Decline
- Stock Market Trends: Analyzing France's CAC 40 Decline
- Mixed Markets: Analyzing Germany's Stock Performance